Last checked at 
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical trial results on its phase three Traumakine study for the treatment of acute respiratory distress syndrome.
The results of the trial are in line with Faron's expectations, it said, as treatment with Traumakine did not result in reduced mortality or an increased number of ventilator free survival days when compared to placebo.
"It appears likely that corticosteroid use diminished the treatment benefit of Traumakine in acute respiratory distress syndrome patients in the Japanese phase three study," said Chief Executive Markku Jalkanen.
"Unfortunately, the use of steroids has become a standard in acute respiratory distress syndrome despite any evidence base and this requires critical reassessment, as the use of steroids appears to worsen outcomes in certain acute respiratory distress syndrome subgroups," added Jalkanen.
Faron shares were trading 1.9% lower on Monday at 58.89 pence each.
